Investment Thesis
SBC Medical exhibits fortress-like financial health with exceptional profitability (29.4% net margin), minimal debt (0.17x D/E ratio), and strong cash generation. However, a significant 15.5% YoY revenue decline coupled with flat net income signals deteriorating growth momentum that warrants caution despite operational excellence.
Strengths
- Exceptional profitability with 29.4% net margin and 38.9% operating margin
- Fortress balance sheet with $163.8M cash, 3.78x current ratio, and minimal leverage (0.17x D/E)
- Strong returns with 20.5% ROE and 13.4% ROA demonstrating efficient capital deployment
- Positive free cash flow generation of $23.3M with low capital intensity (1.4M CapEx)
Risks
- Revenue declined 15.5% YoY - significant top-line deterioration indicating market share loss or demand reduction
- Net income essentially flat despite revenue decline suggests limited growth pathway without further cost-cutting
- Medical services sector exposure to regulatory changes, reimbursement rate pressures, and provider competition
- Minimal insider activity (1 Form 4 in 90 days) suggests limited insider confidence
Key Metrics to Watch
- Quarterly revenue trend to confirm stabilization or continued decline
- Patient volume and average revenue per patient to diagnose revenue pressure source
- Operating margin sustainability as cost-cutting capacity becomes exhausted
Financial Metrics
Revenue
173.6M
Net Income
51.0M
EPS (Diluted)
$0.50
Free Cash Flow
23.3M
Total Assets
380.4M
Cash
163.8M
Profitability Ratios
Gross Margin
73.3%
Operating Margin
38.9%
Net Margin
29.4%
ROE
20.5%
ROA
13.4%
FCF Margin
13.4%
Balance Sheet & Liquidity
Current Ratio
3.78x
Quick Ratio
3.74x
Debt/Equity
0.17x
Debt/Assets
30.8%
Interest Coverage
455.26x
Long-term Debt
42.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T10:33:20.507778 |
Data as of: 2025-12-31 |
Powered by Claude AI